Celgene showcases strong Otezla data in psoriatic arthritis

pharmafile | June 13, 2018 | News story | Research and Development Celgene, EULAR, otezla, pharma 

Celgene has seized the opportunity at the Annual European Congress of Rheumatology in Amsterdam to reveal positive new data for its phosphodiesterase 4 (PDE4) inhibitor Otezla (apremilast) in the treatment of active psoriatic arthritis in patients whose disease has progressed despite the use of prior conventional disease-modifying anti-rheumatic drugs and/or biologics.

The data demonstrated a number of clinically meaningful benefits in patients who failed to achieve an ACR20 response after 104 weeks of treatment with a 30mg, twice-daily dose of Otezla. 58% showed clinically relevant mean reductions in swollen joint count, 42% in tender joint count, and 49% in Physician’s Global Assessment of Disease Activity score. 50% of the 50 patients displaying psoriasis involvement at baseline achieved a PASI-50 score, 68% of the 44 patients with dactylitis saw their disease count reduced to zero, and 34% of the 74 patients with enthesitis achieved a Maastricht Ankylosing Spondylitis Enthesitis Score of zero.

Additionally, in a separate analysis of 374 patients treated with Otezla, it was found that participants with moderate disease activity levels who were still taking part in the study after a year had a 41% chance of achieving low disease activity and a 12% chance of remission after one year.  

“These results demonstrate that with Otezla, some adult patients with active psoriatic arthritis may experience meaningful clinical improvements that are not completely captured by the assessment of ACR20 response criteria,” explained Dr Professor Pascal Richette, Professor of Rheumatology, Laboirisière Hospital in Paris, France. “In addition, the studies underscore the importance of following recommendations from GRAPPA (the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) to consider all six domains of the disease –  peripheral arthritis, enthesitis, dactylitis, axial disease, skin disease and nail disease – when determining treatment regimens.”

Volker Koscielny, Celgene’s Vice President Global Medical Affairs, Inflammation & Immunology, added: “The Palace clinical trial programme continues to provide important learnings about Otezla for the treatment of psoriatic arthritis as well as additional understanding of the long-term management of people living with this chronic condition. This new analysis suggests that adult patients with active psoriatic arthritis with moderate disease activity and a limited number of joints involved may be particularly suitable for treatment with Otezla. This is important information for physicians treating moderate patients who may be looking for additional options.”

Matt Fellows

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …


Novartis acquires Chinook Therapeutics for $3.5bn

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …

Latest content